Company research
Vir Biotechnology, Inc.
CIK 1706431Updated Nov 17, 2026
VIR price & chart
Loading TradingView…
NASDAQ:VIR on TradingView ↗About the company
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.
In the news
Recent filings
424B5 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
424B5 filing
S-3ASR filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,019,453,000Source | 1,498,356,000Source | 1,214,806,000Source | 1,192,532,000Source | 1,669,555,000Source | 1,025,585,000Source | 1,307,727,000Source | 1,793,969,000Source | 1,002,823,000Source | 1,398,813,000Source | 1,919,060,000Source | 2,802,088,000Source |
| Property, Plant and Equipment, NetUSD | 58,203,000Source | 64,791,000Source | 50,430,000Source | 60,795,000Source | 66,063,000Source | 53,158,000Source | 61,681,000Source | 92,477,000Source | 55,620,000Source | 63,183,000Source | 96,018,000Source | 105,609,000Source |
| GoodwillUSD | 16,937,000Source | 16,938,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,924,000Source | 19,258,000Source | 7,702,000Source | 7,998,000Source | 18,899,000Source | 7,777,000Source | 8,072,000Source | 22,465,000Source | 7,850,000Source | 8,120,000Source | 22,565,000Source | 32,755,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 170,084,000Source | 168,350,000Source | 278,729,000Source | 211,104,000Source | 296,864,000Source | 274,161,000Source | 273,571,000Source | 160,711,000Source | 232,185,000Source | 222,947,000Source | 241,576,000Source | 848,631,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Assets, CurrentUSD | 545,684,000Source | 1,047,157,000Source | 573,739,000Source | 735,706,000Source | 1,205,740,000Source | 522,985,000Source | 932,207,000Source | 1,213,097,000Source | 514,080,000Source | 1,042,458,000Source | 1,588,226,000Source | 2,519,077,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 36,956,000Source | 43,085,000Source | 39,084,000Source | 41,469,000Source | 40,729,000Source | 44,761,000Source | 42,394,000Source | 49,999,000Source | 45,143,000Source | 47,725,000Source | 52,549,000Source | 104,356,000Source |
| Operating Lease, Right-of-Use AssetUSD | 63,555,000Source | 60,779,000Source | 59,391,000Source | 64,853,000Source | 62,266,000Source | 60,760,000Source | 58,559,000Source | 70,346,000Source | 62,099,000Source | 59,680,000Source | 71,182,000Source | 82,557,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 223,355,000Source | 257,629,000Source | 232,313,000Source | 245,060,000Source | 235,885,000Source | 212,820,000Source | 263,908,000Source | 246,613,000Source | 237,547,000Source | 248,428,000Source | 328,824,000Source | 724,125,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 14,000Source | 14,000Source | 17,000Source | 14,000Source | 14,000Source | 16,000Source | 14,000Source | 14,000Source | 14,000Source | 14,000Source | 13,000Source | 13,000Source |
| Additional Paid in CapitalUSD | 1,952,843,000Source | 1,894,781,000Source | 2,230,464,000Source | 1,941,386,000Source | 1,878,013,000Source | 2,139,698,000Source | 1,926,529,000Source | 1,852,839,000Source | 1,965,090,000Source | 1,911,872,000Source | 1,828,862,000Source | 1,709,835,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,154,848,000Source | -655,195,000Source | -1,243,386,000Source | -991,707,000Source | -441,478,000Source | -1,323,466,000Source | -880,749,000Source | -303,100,000Source | -1,197,771,000Source | -759,784,000Source | -237,824,000Source | 377,237,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,911,000Source | 1,127,000Source | -4,602,000Source | -2,221,000Source | -2,879,000Source | -3,483,000Source | -1,975,000Source | -2,397,000Source | -2,057,000Source | -1,717,000Source | -815,000Source | -9,122,000Source |
| Stockholders' Equity Attributable to ParentUSD | 796,098,000Source | 1,240,727,000Source | 982,493,000Source | 947,472,000Source | 1,433,670,000Source | 812,765,000Source | 1,043,819,000Source | 1,547,356,000Source | — | — | — | 2,077,963,000Source |
| Liabilities and EquityUSD | 1,019,453,000Source | 1,498,356,000Source | 1,214,806,000Source | 1,192,532,000Source | 1,669,555,000Source | 1,025,585,000Source | 1,307,727,000Source | 1,793,969,000Source | 1,002,823,000Source | 1,398,813,000Source | 1,919,060,000Source | 2,802,088,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 75,222,000Source | 117,161,000Source | 94,961,000Source | 105,004,000Source | 96,412,000Source | 73,558,000Source | 137,286,000Source | 94,068,000Source | 92,815,000Source | 119,662,000Source | 175,407,000Source | 511,029,000Source |
| Operating Lease, Liability, CurrentUSD | 8,960,000Source | 19,408,000Source | 9,137,000Source | 8,825,000Source | 19,495,000Source | 8,944,000Source | 7,925,000Source | 11,913,000Source | 8,798,000Source | 7,752,000Source | 12,867,000Source | 4,137,000Source |
| Accounts Payable, CurrentUSD | 6,847,000Source | 7,305,000Source | 17,754,000Source | 12,234,000Source | 4,389,000Source | 5,445,000Source | 3,725,000Source | 7,114,000Source | 9,803,000Source | 5,081,000Source | 6,334,000Source | 6,422,000Source |
| Operating Lease, Liability, NoncurrentUSD | 91,215,000Source | 93,405,000Source | 84,137,000Source | 93,405,000Source | 95,018,000Source | 86,635,000Source | 88,170,000Source | 109,171,000Source | 89,054,000Source | 90,139,000Source | 111,673,000Source | 123,837,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 3,253,000Source |
| Other Liabilities, NoncurrentUSD | 13,305,000Source | 13,893,000Source | 18,875,000Source | 13,031,000Source | 13,855,000Source | 19,417,000Source | 14,812,000Source | 14,238,000Source | 21,578,000Source | 14,577,000Source | 14,258,000Source | 7,862,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 1,190,000,000Source | — | — | 1,430,000,000Source | — | — | 1,510,000,000Source | — | — | 1,630,000,000Source | 2,400,000,000Source |
| Deferred Revenue, CurrentUSD | 0Source | 15,198,000Source | — | 10,109,000Source | 16,702,000Source | — | 11,935,000Source | 14,694,000Source | — | 12,648,000Source | 64,853,000Source | 15,517,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | — | — | — | — | 1,526,000Source | — | — | 1,526,000Source | 53,207,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | 2,190,000Source | 3,253,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | -213,717,000Source | — | — | — | — | -437,987,000Source | -521,960,000Source | -615,117,000Source | 515,837,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 2,811,000Source | 2,867,000Source | 11,680,000Source | 14,559,000Source | 18,920,000Source | 6,251,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 12,087,000Source | 14,059,000Source | 49,072,000Source | 78,457,000Source | 111,316,000Source | 102,082,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | 6,513,000Source | 565,000Source | -770,038,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -4,226,000Source | -1,415,000Source | 4,997,000Source | -988,000Source | 732,000Source | 797,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 304,000Source | -2,949,000Source | -1,063,000Source | -15,186,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -132,386,000Source | -78,116,000Source | -391,781,000Source | -446,352,000Source | -778,785,000Source | 1,663,253,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 11,835,000Source | 126,818,000Source | 310,371,000Source | 499,367,000Source | 164,629,000Source | -1,193,461,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 390,000Source | 1,629,000Source | 4,832,000Source | 7,301,000Source | 21,573,000Source | 68,028,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 162,523,000Source | 598,000Source | 3,785,000Source | 4,388,000Source | 7,480,000Source | 34,761,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | -361,000Source | -165,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 41,972,000Source | 49,300,000Source | -77,625,000Source | 57,403,000Source | -606,676,000Source | 504,553,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 179,256,000Source | 264,330,000Source | 287,602,000Source | 306,278,000Source | 283,042,000Source | 367,995,000Source | 241,070,000Source | 318,695,000Source | 261,292,000Source | 867,968,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 2,420,000Source | 786,000Source | 2,676,000Source | 252,030,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 11,356,000Source | 16,697,000Source | 12,391,000Source | 12,451,000Source | 12,087,000Source | 14,059,000Source | 49,072,000Source | 78,457,000Source | 111,316,000Source | 102,082,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 531,000Source | 532,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 1,190,000,000Source | — | — | — | — | — | — | 1,630,000,000Source | 2,400,000,000Source |
| DepreciationUSD | — | — | 2,900,000Source | 2,900,000Source | 2,700,000Source | 2,900,000Source | 2,700,000Source | 2,800,000Source | 11,400,000Source | 14,200,000Source | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 1,335,000Source | 1,130,000Source | -1,723,000Source | -3,382,000Source | -170,000Source | 6,382,000Source | 1,729,000Source | -5,528,000Source | -21,888,000Source | -111,140,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| GoodwillUSD | — | — | 16,937,000Source | 16,938,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source | 16,937,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 14,550,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | — | 9,658,000Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 168,000Source | 177,000Source | 179,000Source | 170,000Source | 170,000Source | 16,000Source | 217,000Source | -1,145,000Source | -13,077,000Source | 238,443,000Source |
| Investment Income, InterestUSD | — | — | 9,363,000Source | 17,527,000Source | 8,966,000Source | 10,785,000Source | 7,189,000Source | 12,288,000Source | 40,238,000Source | 71,809,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -163,141,000Source | -213,717,000Source | 80,080,000Source | -110,958,000Source | -125,695,000Source | -120,965,000Source | -437,987,000Source | -521,960,000Source | -615,117,000Source | 515,837,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -615,061,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 10,470,000Source | 17,764,000Source | 6,792,000Source | 7,629,000Source | 6,765,000Source | 18,598,000Source | 41,558,000Source | 64,060,000Source | 56,111,000Source | -78,788,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -228,000Source | -893,000Source | -451,000Source | 226,000Source | -254,000Source | -72,000Source | -409,000Source | -2,221,000Source | -8,991,000Source | 4,260,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 158,374,000Source | 173,694,000Source | 886,334,000Source | 1,235,339,000Source | 2,016,189,000Source | 1,476,965,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 162,349,000Source | 0Source | — | — | — | 0Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 174,000Source | 598,000Source | 1,349,000Source | 790,000Source | 3,484,000Source | 4,534,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | — | — | 0Source | 12,712,000Source | 0Source | -172,000Source | 0Source | -10,000Source | -182,000Source | 34,995,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 240,000Source | 2,380,000Source | 238,946,000Source | 1,214,000Source | -29,000Source | 3,032,000Source | 68,556,000Source | 74,205,000Source | 86,180,000Source | 1,615,797,000Source |
| Cost of Goods and Services Sold | — | — | — | —Source | —Source | —Source | — | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 22,231,000Source | 25,744,000Source | 30,196,000Source | 22,283,000Source | 23,339,000Source | 23,944,000Source | 92,074,000Source | 119,031,000Source | 178,049,000Source | 161,762,000Source |
| Operating Income (Loss)USD | — | — | -173,443,000Source | -231,304,000Source | 73,467,000Source | -118,417,000Source | -132,290,000Source | -139,547,000Source | -479,328,000Source | -587,165,000Source | -684,305,000Source | 833,068,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -228,000Source | -893,000Source | -451,000Source | 226,000Source | -254,000Source | -72,000Source | -409,000Source | -2,221,000Source | -8,991,000Source | 4,260,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -162,973,000Source | -213,540,000Source | 80,259,000Source | -110,788,000Source | -125,525,000Source | -120,949,000Source | -437,770,000Source | -523,105,000Source | -628,194,000Source | 754,280,000Source |
| Income Tax Expense (Benefit)USD | — | — | 168,000Source | 177,000Source | 179,000Source | 170,000Source | 170,000Source | 16,000Source | 217,000Source | -1,145,000Source | -13,077,000Source | 238,443,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -163,141,000Source | -213,717,000Source | 80,080,000Source | -110,958,000Source | -125,695,000Source | -120,965,000Source | -437,987,000Source | -521,960,000Source | -615,117,000Source | 515,837,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.17Source | -1.56Source | 0.48Source | -0.8Source | -0.85Source | -0.88Source | -3.16Source | -3.83Source | -4.59Source | 3.89Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.17Source | -1.56Source | 0.47Source | -0.8Source | -0.85Source | -0.88Source | -3.16Source | -3.83Source | -4.59Source | 3.83Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 138,930,173Source | 136,653,753Source | 167,719,015Source | 138,447,469Source | 147,356,811Source | 137,468,900Source | 138,520,419Source | 136,246,865Source | 134,130,924Source | 132,606,767Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 138,930,173Source | 136,653,753Source | 168,879,127Source | 138,447,469Source | 147,356,811Source | 137,468,900Source | 138,520,419Source | 136,246,865Source | 134,130,924Source | 134,810,908Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 531,000Source | 532,000Source |
| Costs and ExpensesUSD | — | — | 173,683,000Source | 233,684,000Source | 165,479,000Source | 119,631,000Source | 132,261,000Source | 142,579,000Source | 547,884,000Source | 661,370,000Source | 770,485,000Source | 782,729,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -87,000Source | 1,804,000Source | -12,014,000Source | 253,629,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -448,370,000Source | -499,680,000Source | -608,134,000Source | 692,445,000Source |
| Investment Income, InterestUSD | — | — | 9,363,000Source | 17,527,000Source | 8,966,000Source | 10,785,000Source | 7,189,000Source | 12,288,000Source | 40,238,000Source | 71,809,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | -615,061,000Source | — |
| Nonoperating Income (Expense)USD | — | — | 10,470,000Source | 17,764,000Source | 6,792,000Source | 7,629,000Source | 6,765,000Source | 18,598,000Source | 41,558,000Source | 64,060,000Source | 56,111,000Source | -78,788,000Source |
| Research and Development ExpenseUSD | — | — | 151,463,000Source | 195,178,000Source | 135,283,000Source | 97,509,000Source | 108,922,000Source | 118,645,000Source | 455,966,000Source | 506,499,000Source | 589,671,000Source | 474,648,000Source |
Offerings
Registration 333-299995
Filing attachments
d156106dex991.htm · 8-K · 2026-11-16
Exhibit 99.1 Vir Biotechnology Announces Proposed Public Offering SAN FRANCISCO, November 12, 2026 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-…
Read attachment ↗d156106dex992.htm · 8-K · 2026-11-16
Exhibit 99.2 Vir Biotechnology Announces Pricing of Public Offering SAN FRANCISCO, November 12, 2026 - Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to…
Read attachment ↗d187683dex43.htm · S-3ASR · 2026-11-12
Exhibit 4.3 VIR BIOTECHNOLOGY, INC. and Trustee INDENTURE Dated as of _______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture ──────────────────────────────────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) …
Read attachment ↗d187683dex44.htm · S-3ASR · 2026-11-12
Exhibit 4.4 VIR BIOTECHNOLOGY, INC. and Trustee INDENTURE Dated as of _______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture ──────────────────────────────────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 …
Read attachment ↗d187683dex45.htm · S-3ASR · 2026-11-12
Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF S…
Read attachment ↗d187683dex46.htm · S-3ASR · 2026-11-12
Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINE…
Read attachment ↗